Literature DB >> 12399744

Intravascular B-cell lymphoma.

Nóra Erös1, Zsuzsánna Károlyi, Anikó Kovács, István Takács, Gáspár Radványi, Gábor Kelényi.   

Abstract

Intravascular (angiotropic) lymphoma is a unique and rare cutaneous lymphoma in which the malignant T or B lymphoid cells proliferate within the lumens of small blood vessels, primarily in the skin and central nervous system. Erythematous, tender nodules, tumors, and telangiectases are the most common skin symptoms in addition to various neurologic signs. Progression of the disease produces secondary organ involvement with variable symptoms and can be fatal. We describe a case of a 74-year-old woman with edematous, infiltrated, orange-like skin with multiple telangiectases, generalized edema, severe weakness, and extremely high values of lactate dehydrogenase. Skin biopsy specimens revealed atypical large cells filling up the lumens of dermal capillaries. Immunohistochemical investigation results identified them as B cells with CD20, CD45, CD79a, Ki-67, and HLA-DR positivity. After administration of diuretics, colchicine, and systemic PUVA therapy, the patient lost her edema, her skin became tender and free of telangiectases, and laboratory alterations normalized. Because of heavy neuralgia in her legs, oral monochemotherapy was introduced with chlorambucil, and now the patient is in remission.

Entities:  

Mesh:

Year:  2002        PMID: 12399744     DOI: 10.1067/mjd.2002.108493

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  2 in total

1.  [Malignant lymphoma of the skin: update on diagnostics and therapy of primary cutaneous B-cell lymphoma].

Authors:  C Hallermann; C Niermann; M Fluck; A-R Fischedick; H-J Schulze
Journal:  Hautarzt       Date:  2011-12       Impact factor: 0.751

2.  [Intravascular lymphoma: two case reports demonstrating the heterogeneity of the disease].

Authors:  I Satzger; B Völker; D Kofahl-Krause; A Ganser; A Kapp; R Gutzmer
Journal:  Hautarzt       Date:  2009-02       Impact factor: 0.751

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.